Close Menu
    Tripoli WireTripoli Wire
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Tripoli WireTripoli Wire
    Home » MoHAP and WHO host scientific symposium on malaria control
    Health

    MoHAP and WHO host scientific symposium on malaria control

    June 14, 2022
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    In cooperation with the World Health Organization (WHO), the UAE Ministry of Health and Prevention (MoHAP) held a scientific symposium on malaria to discuss the latest global developments relating to the illness and to review the UAE’s effective strategy to prevent and control communicable diseases.

    MoHAP and WHO host scientific symposium on malaria controlDr. Hussain Abdul Rahman Al Rand, Assistant Under-Secretary for Public Health, attended the event in celebration of the country’s 15th anniversary of being malaria-free. Members of the WHO and its Eastern Mediterranean Regional Office attended, along with representatives from Tadweer Company, Sheikh Khalifa Medical City (SKMC) and the National Centre for Malaria Vector Control.

    Related Posts

    WHO maps three-month path for Congo Ebola containment

    August 19, 2026

    DRC malaria cases surpass 26 million in 2025

    August 17, 2026

    DR Congo Ebola death toll tops 1,900 as cases rise

    August 11, 2026

    Obesity linked to 8.2% of Belgium deaths in new health report

    August 8, 2026

    Moderna begins Ebola vaccine trial amid DR Congo outbreak

    August 5, 2026

    Michigan reports first deaths tied to cyclospora outbreak

    August 4, 2026
    Latest News

    Wall Street rises after Treasury expands debt buybacks

    August 20, 2026

    Healthcare shares strengthen market gains
    Healthcare stocks provided another source of support during Wednesday’s session as several pharmaceutical shares recorded large gains. Moderna shares surged 177%, while Merck advanced 12.6% after the companies announced positive results from a Phase 3 melanoma trial. The INTerpath-001 study tested personalized mRNA therapy intismeran autogene with Keytruda following surgical removal of high-risk melanoma. The combination met its primary endpoint for recurrence-free survival. It also met a key secondary endpoint measuring survival without distant cancer spread.

    WHO maps three-month path for Congo Ebola containment

    August 19, 2026

    Indonesia 6.1 earthquake rattles North Sumatra coast

    August 19, 2026

    DRC Ebola outbreak sets national death toll record

    August 17, 2026

    DRC malaria cases surpass 26 million in 2025

    August 17, 2026

    South Korea auto exports reach $6.24 billion in July

    August 14, 2026

    Total solar eclipse crosses Russian Arctic and Europe

    August 13, 2026

    International Youth Day 2026 puts youth inclusion in focus

    August 13, 2026
    © 2026 Tripoli Wire | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.